extracellular HMGB1 has been identified as a proinflammatory mediator that promotes immune responses by binding to pattern recognition receptors, including TLRs and the receptor for advanced glycation end products (RAGE) (17) (18) (19) (20) (21) (22) (23) , which are involved in inflammatory processes and have the ability to activate a common signaling pathway that culminates in the activation of NF-kB transcription factors. HMGB1 mediates cellular signaling through RAGE, TLR2, and TLR4 receptors to activate the intracellular signal of MAPKs and NF-kB (17) (18) (19) . The interaction of HMGB1 with TLR2 or TLR4 mediates HMGB1's proinflammatory actions, whereas its interaction with RAGE activates NF-kB. As one of the most important downstream molecules in TLR signaling pathways, NF-kB is required for the gene expression of many inflammatory mediators, such as IL-1b, TNF-a, and IL-6 (18, (24) (25) (26) . HMGB1 is actively secreted by a variety of innate immune cells, is passively released by necrotic cells, and drives inflammation and/or repair (10) (11) (12) (13) (14) (15) . Once HMGB1 is released into the extracellular milieu, it acts as a proinflammatory mediator by activating a wide range of inflammatory responses including the robust release of cytokines (27, 28) . Recently, we showed that RSV-induced oxidative stress promotes HMGB1 extracellular release and triggers an inflammatory response, implicating the involvement of HMGB1 in RSV pathogenesis (29) .
In order to better understand the early pathways of RSV pathogenesis and the immune response to this virus, we explored the proinflammatory activity of HMGB1 on various immune cells in the context of RSV infection and the mechanisms underlying HMGB1 release. We further studied the proinflammatory effects of HMGB1 on immune cells via activation of NF-kB and P38 MAPK signaling pathways. In this study, we demonstrate that RSV-induced HMGB1 release from airway epithelial cells (AECs) (A549 and small alveolar epithelial [SAE] cells) is mediated in part by NF-kB and TLR4. Human primary immune cells (PBMCs, PBMC-derived monocytes, macrophages [MFs], dendritic cells [DCs] , and eosinophils [EOS] as well as THP-1 monocytes, THP-1 monocyte-derived MFs, and EOL1 cells) stimulated in vitro with purified HMGB1 (recombinant HMGB1 [rHMGB1] and secreted HMGB1 [sHMGB1]) induce the secretion of proinflammatory cytokines and chemokines, which involves the activation of P38 MAPK and NF-kB pathways. These results suggested that HMGB1 acts as a signaling molecule to directly activate immune cells, and its interaction with signaling pathways contributes to the inflammatory response to RSV infection. This study uncovers a hitherto underappreciated role for HMGB1 in driving inflammatory responses during RSV infection that will facilitate discovery of novel therapeutic strategies for the treatment of RSVinduced human diseases.
Materials and Methods
Reagents F12K medium, EDTA, and HBSS without Mg 2+ or Ca 2+ were purchased from Life Technologies-BRL (Grand Island, NY). Novex 10, 12, 4-12, and 4-20% mini gels and DAPI were obtained from Invitrogen (Carlsbad, CA). HEPES and RPMI 1640 were from Corning Cellgro (Manassas, VA). SAE cell growth media was from Lonza (Houston, TX). Dextran, Bay 11-7085, PMA, LPS, and trypan blue were obtained from Sigma-Aldrich (St. Louis, MO). The 103 Tris glycine buffer, 103 Tris glycine-SDS electrophoresis buffer, RC DC Protein Assay kit, Bio-Plex Human Cytokine 27-Plex kit, and Bio-Rad Protein Assay reagent were from Bio-Rad Laboratories (Hercules, CA). Amersham Full-Range Rainbow Molecular Weight Markers and Hybond polyvinylidene difluoride membrane (PVDF) were from GE Healthcare (Piscataway, NJ). Immobilon Western HRP substrate and ProteoExtract Subcellular Proteome Extraction kit were obtained from EMD Millipore (Billerica, MA). Recombinant human HMGB1 and mouse monoclonal human RAGE Ab were purchased from R&D Systems (Minneapolis, MN). The recombinant human cytokines GM-CSF and IL-4 were from PeproTech (Rocky Hill, NJ). VarioMACS separation columns, MACS Separator (magnetic), and CD16 and CD14 MicroBeads were from Miltenyi Biotec (Auburn, CA). Rabbit polyclonal anti-human HMGB1 Ab and mouse monoclonal anti-TLR4 Ab were from Abcam (Cambridge, MA). Mouse monoclonal anti-b-actin Ab was from Sigma-Aldrich. Phospho-NF-kB p65 (Ser536) rabbit mAb, phospho-P38 MAPK (Thr180/Tyr182) rabbit mAb, goat anti-mouse IgG HRP, and goat antirabbit IgG-HRP were from Cell Signaling Technology (Danvers, MA), and the FITC-conjugated secondary Ab was from SouthernBiotech (Birmingham, AL).
Ethics statement
The use of plasma and PBMC samples in this study was conducted with the approval of the Institutional Review Board (IRB) at the University of Texas Medical Branch in Galveston in accordance with its guidelines for the protection of human subjects (IRB no. 04-371). All participants gave written informed consent to participate in the study.
RSV preparation
For RSV stock preparation, the RSV Long strain was grown in HEp-2 cells and purified by centrifugation on discontinuous sucrose gradients as described previously (30, 31) . The virus titer of the purified RSV pools was 8-9 log 10 PFU/ml using a methylcellulose plaque assay (32) . No contaminating cytokines were found in these sucrose-purified viral preparations. LPS was not detected using the limulus hemocyanin agglutination assay. Virus pools were aliquoted, quick-frozen on dry ice/alcohol, and stored at 280˚C until used.
Cell culture and RSV infection of AECs
The human AEC line A549 (human alveolar type II-like epithelial cell line; American Type Culture Collection, Manassas, VA) and SAE cells, which are primary human AECs derived from terminal bronchioli of cadaveric donors (Lonza, San Diego, CA), were grown according to the manufacturer's instructions. A549 cells were cultured and maintained in F12K medium containing 10% FBS, 2 mM glutamine, 100 IU/ml penicillin, and 100 mg/ml streptomycin. SAE cells were maintained in SAE cell growth media containing 7.5 mg/ml bovine pituitary extract, 0.5 mg/ml hydrocortisone, 0.5 mg/ml human epidermal growth factor, 0.5 mg/ml epinephrine, 10 mg/ml transferrin, 5 mg/ml insulin, 0.1 mg/ml retinoic acid, 0.5 mg/ml triiodothyronine, 50 mg/ml gentamicin, and 50 mg/ml BSA. Monolayers of undifferentiated SAE cells were cultured in 25-cm 2 flasks at 37˚C and 5% CO 2 with an SAE cell basal media supplied with growth factors. Cells were used in the experiments at passage three (31) . When SAE cells were used for RSV infection, the cells were changed to basal medium and not supplemented with growth factors 6 h prior to and throughout the length of the experiment. At 80-90% confluency, cell monolayers were infected with RSV at multiplicity of infection (MOI) of 1 (unless otherwise stated), as previously described (33) . An equivalent amount of a 30% sucrose solution was added to uninfected A549 and SAE cells as a control. In some experiments, cells were pretreated with Bay 11-7085, PMA, rHMGB1, sHMGB1, TLR4 mAb, or RAGE mAb for 1 h and then infected with RSV in the presence of the selected compound. The total number of cells and cell viability were measured by trypan blue exclusion. There was no significant change in cell viability when cells were incubated in the presence of sHMGB1, rHMGB1, Bay 11, or PMA.
Isolation of human immune cells from human peripheral blood and viral infection
Peripheral blood (60 ml) was drawn from healthy, nonsmoking individuals (18-50 y old) as we previously reported, under a research protocol approved by the IRB committee at the University of Texas Medical Branch (29) . PBMCs were isolated from whole blood using Ficoll-Hypaque, and monocytes were purified using magnetic CD14 MicroBeads (Miltenyi Biotec, Sunnyvale, CA). Primary monocyte-derived MFs were obtained after 6 d of differentiation in RPMI 1640 medium supplemented with 2 mM L-glutamine, 10% FBS, 50 mM 2-ME, 1000 U/L penicillin/streptomycin, and 10 ng/ml M-CSF. EOS were obtained by sedimentation in 4-6% dextran for 30 min at room temperature (RT), followed by centrifugation in a Ficoll-Hypaque gradient as described previously (34) . Following centrifugation at 500 3 g, upper layers of plasma and mononuclear cells were removed and saved for further analysis. EOS isolation used hypotonic lysis for elimination of erythrocytes and negative selection using a combination of anti-CD16, anti-CD3, anti-CD235, and anti-CD14 MicroBeads to remove neutrophils and other contaminating cells using the MACS system 9 (Miltenyi Biotec). EOS purity was consistently monitored by Hansel staining and typically ranged above 98%. Monocyte contamination was virtually undetectable, and activated EOS were #1%. Primary monocyte-derived DCs were obtained after 5 d of differentiation in RPMI 1640 supplemented with 10% FBS, 2 mM L-glutamine containing 1500 U/ml IL-4, and 1600 U/ml GM-CSF. THP-1 monocyte-derived MFs were obtained by culturing the cells with 10 ng/ml PMA for 72 h. Cells (5 3 10 5 ) were pretreated with 100 ml of rHMGB1 or sHMGB1 at 100 ng/ml for 1 h, followed by infection with RSV at an MOI of 3 for 1-2 h at 37˚C and then washed twice with RPMI 1640. For the remaining time of infection, the cells were placed in a 24-well plate in a total volume of 1 ml of RPMI 1640. Cytoplasmic and nuclear fractions were prepared from MFs using ProteoExtract Subcellular Proteome Extraction kit from EMD Millipore.
Purification of RSV-infected A549 cell-sHMGB1
sHMGB1 was purified from RSV-infected A549 cells to compare with rHMGB1 and evaluate its biological activity. A549 cells were cultured as described above and infected with RSV at an MOI of 1 in serum-free medium. Cell culture supernatants were centrifuged (12,000 3 g, 10 min, 4˚C) and stored at 280˚C until further use. Western blot (WB) analysis with an anti-HMGB1 Ab preparation described above was used to determine the presence of sHMGB1 in the cell culture medium. The cell culture medium (∼1.5 l) was thawed and purified using a combination of anion exchange chromatography and cation exchange chromatography. Eluted fractions were evaluated for the presence of HMGB1 by WB analysis with anti-HMGB1 Ab. The sHMGB1 corresponding fractions were combined and were further purified by an anion exchange chromatography step. The eluted fractions were evaluated for sHMGB1 using immunologic dot blotting with anti-HMGB1 Ab. The sHMGB1 peak was pooled and further purified by cation exchange chromatography. 
Measurement of cytokines

Western blotting and densitometric analyses
Total cell lysates were prepared from uninfected, RSV-infected, TLR4 mAb, RAGE mAb, Bay 11, PMA-and HMGB1-treated A549, SAE cells, PBMCs, monocytes, MFs, EOS, DCs, THP-1 monocytes, THP-1 monocyte-derived MFs, and EOL1 cells by adding ice-cold lysis buffer (50 mM Tris-HCl, pH 7.4, containing 150 mM NaCl, 1 mM EGTA, 0.25% sodium deoxycholate, 1 mM Na 3 VO 4 , 1 mM NaF, 1% Triton X-100, and 1 mg/ml aprotinin, leupeptin, and pepstatin). After incubation on ice for 10 min, the lysates were centrifuged at 4˚C at 14,000 3 g to remove the detergent insoluble cell debris. Proteins (10-20 mg/sample) were boiled in 23 Laemmli buffer and fractionated by SDS-PAGE. Proteins were then transferred onto a Hybond polyvinylidene difluoride membrane (Amersham, Piscataway, NJ), and the membranes were incubated for 30 min in TBST (10 mM Tris-HCl, pH 7.6, containing 150 mM NaCl, 0.05% Tween 20) and 5% BSA. After blocking of the nonspecific binding sites, membranes were washed with TBST and then incubated sequentially, first with the primary Ab overnight at 4˚C and then with anti-rabbit peroxidase-conjugated secondary Ab (1:10,000 in TBST) at RT for 30 min. Membranes were washed, and signal was detected using ECL substrate (Amersham) according to the manufacturer's protocol. The primary Abs for WBs were anti-HMGB1 rabbit polyclonal Ab, phospho-NF-kB p65 (Ser536) rabbit mAb, phospho-P38 MAPK (Thr180/Tyr182) rabbit mAb, and anti-b-actin mAb. The secondary Abs were goat anti-mouse IgG HRP and goat anti-rabbit IgG-HRP. Densitometric analysis of WB band intensities was performed using ImageJ (National Institutes of Health) software.
Immunocytochemistry
Cells were cultured in Lab-Tek II chambers (Nalge Nunc, Penfield, NY) and fixed in 4% paraformaldehyde in PBS at RT for 30 min. The cells were then washed with PBS and incubated at 4˚C for 10 min with permeabilization buffer (PBS containing 0.1% Triton X-100). After blocking with 5% BSA in PBS for 1 h, cells were incubated with anti-HMGB1 Ab (Abcam), followed by incubation for 1 h with Alexa Fluor 488-conjugated or FITC-conjugated secondary Ab (Invitrogen). The cells were coverslip-mounted using mounting medium containing the fluorescent nuclear stain DAPI (Invitrogen), and signals were analyzed using a fluorescence microscope (Nikon).
Statistics
A two-tailed Student t test using 95% confidence levels was performed in all experiments using Graph PAD Prism 5.02. Significance is presented as *p , 0.05, **p , 0.005, and ***p , 0.0005.
Results
HMGB1 activates the NF-kB and P38 MAPK pathway in AECs but does not induce release of proinflammatory mediators
AECs are the major targets of RSV infection and have been shown to secrete a variety of proinflammatory molecules that regulate the FIGURE 1. The effect of purified HMGB1 on NF-kB (P65) and P38 MAPK activation in human AECs. A549 (A and C) and SAE (B and D) cells were treated with rHMGB1 (100 ng/ml) and mock-infected or infected with RSV at an MOI of 1. Cell-free supernatants and total cell lysates were prepared after 24 h p.i. to measure HMGB1, pP65, and pP38 by WB (A and B). Densitometric analysis of WB band intensities were performed using ImageJ software and were normalized to internal loading control b-actin for lysates (C and D). The figure is representative of three independent experiments, and quantified results are shown in bar graphs. *p , 0.05, **p , 0.005, ***p , 0.0005. migration and activation of leukocytes and play a key role in inflammatory and infectious processes in the lung (35, 36) . We previously showed that RSV infection induces significant HMGB1 extracellular release by AECs, and addition of rHMGB1 did not by itself induce the release of cytokines/chemokines from A549 cells (29) . In this study, we further confirmed these results with the addition of sHMGB1 purified from RSV-infected A549 cell culture supernatants. A549 cells were incubated with sHMGB1 and/or rHMGB1 at 100 ng/ml followed by infection with RSV at an MOI of 1, and proinflammatory mediator release was measured after 24 h postinfection (p.i.) in the cell-free supernatants using a Bio-Plex assay. Total cell lysates were used to measure phosphorylation of NF-kB (pP65 ser536) and P38 MAPK (Thr180/Tyr182) by WB. A549 cells did not release proinflammatory mediators with the addition of purified HMGB1 (Supplemental Fig. 1A, 1B ) (29) . However, both sHMGB1 and rHMGB1 treatment of the A549 cells in the presence or absence of RSV resulted in a significant increase in the release of IL-8 and MCP-1, compared with untreated/RSVinfected cells, suggesting that HMGB1 provides a danger signal to the cells in eliciting proinflammatory gene expression in RSVinfected A549 cells (Supplemental Fig. 1A ). To confirm these results, we also examined the effect of purified HMGB1 on primary human SAE cells, which are derived from terminal bronchioles of a normal individual. Similar findings were observed in SAE cells in which HMGB1 did not have any effect on the release of proinflammatory mediators (Supplemental Fig. 1B ).
NF-kB is a multisubunit molecule that belongs to the REL family of transcription factors involved in the regulation of large number of genes that control various aspects of the immune and inflammatory response, and its activation is triggered by a variety of stimuli, including RSV (36, 37) . The P38 MAP kinase signaling pathway plays a central role in regulating cellular inflammatory and stress responses, protein synthesis, and the production of proinflammatory cytokines (38) . RSV is a potent inducer of NF-kB and P38 MAPK phosphorylation in A549 and SAE cells (33, (39) (40) (41) (42) . In this study, NF-kB and P38 MAPK activation was determined in AECs after purified HMGB1 stimulation by measurement of pP65 and pP38 levels. Addition of rHMGB1 activated NF-kB and P38 MAPK signaling pathways in A549 and SAE cells and was significantly enhanced in the presence of RSV ( Fig. 1A-D ). Densitometric analysis of the WB showed that rHMGB1 treatment of A549 cells increased the pP65 expression by 2.1-fold, and RSV induced a 5.5fold increase when compared with uninfected cells, whereas pP38 MAPK expression was increased by 2.9-fold with rHMGB1 treatment, and RSV infection induced a 3.4-fold increase when compared with uninfected cells. There was a significant increase in both pP65 and pP38 levels in RSV-infected and rHMGB1-treated cells. Similar findings were observed in SAE cells in which rHMGB1 treatment alone increased pP65 levels by 1.5-fold and with RSV infection by 2.7-fold, whereas pP38 levels increased by 1.5-fold with rHMGB1 alone and by 3.4-fold in the presence of RSV. These results indicated that HMGB1 activates the P38 MAPK and NF-kB signaling pathways to promote the inflammatory response.
RSV-induced HMGB1 translocation and extracellular release in AECs was mediated via NF-kB
RSV infection causes significant secretion of HMGB1 from AECs (29) and is a potent inducer of NF-kB in lung epithelial cells (33, 39, 40) . Several studies have demonstrated that HMGB1 activates the NF-kB signal transduction pathway and facilitates several immunosuppressive mechanisms (43) (44) (45) . In this study, we determined that HMGB1 secretion from AECs in response to RSV infection occurs via the NF-kB pathway. We investigated the effect of BAY 11-7085, a small molecule IKKa/b inhibitor of NF-kB activation, and PMA, a potent activator of NF-kB signaling, on RSV-induced HMGB1 release in A549 cells. A549 cells were pretreated either with Bay 11 (250 ng/ml) or PMA (1 mg/ml) and infected with RSV at an MOI of 1, and then we measured HMGB1 in the cell-free supernatants and total cell lysates. Inhibition of NF-kB signaling by Bay 11 significantly blocked HMGB1 release with a concomitant increase in the cellular HMGB1. We observed a decrease of 13.7fold compared with RSV infection alone, which was 56.7-fold higher compared with uninfected cells ( Fig. 2A, 2C ). NF-kB activation by PMA significantly enhanced RSV-induced HMGB1 release compared with each stimulus alone, as we noticed an increase of 36.4-fold compared with RSV infection alone, which was only 23.8-fold higher compared with control cells (Fig. 2B, 2D ). These findings confirm the involvement of NF-kB signaling in RSVinduced HMGB1 release from AECs.
Effects of TLR4 or RAGE mAbs on RSV-induced HMGB1 release and NF-kB activation
Although our findings indicated that RSV infection induces HMGB1 secretion, the molecular basis of its nuclear translocation, mechanism of its release into the extracellular space, and the pathways governing its release are unclear. However, a possible mechanism involved reactive oxygen species generated in RSV-infected AECs due to increased oxidative stress (29) . In order to determine the involvement of TLR4 and RAGE, receptors of HMGB1 signaling, we investigated the effect of blockage of these receptors using mAb. A549 cells were pretreated either with TLR4 mAb (2 mg/ml) or RAGE mAb (2 mg/ml) in the presence or absence of RSV, and HMGB1 levels were measured by WB. Our results showed that pretreating RSV-infected AECs with a TLR4 mAb significantly inhibited RSV-induced HMGB1 release by 0.37-fold (37%) compared with RAGE mAb treatment, suggesting the involvement of TLR4 signaling in RSV-induced HMGB1 secretion (Fig. 3A, 3C) . A slight, but not significant, reduction of RSV-induced HMGB1 release was observed with RAGE mAb pretreatment ( Fig. 3B, 3D ). Activation of NF-kB was also slightly, but not significantly, decreased with TLR4 blockage, whereas blocking RAGE significantly enhanced NF-kB activation ( Fig. 3A-D) . These results suggested that RSV-induced HMGB1 secretion in AECs was mediated through the TLR4 pathway, whereas RAGE blockade had no effect on RSVinduced HMGB1 release.
HMGB1 activated PBMCs to induce an inflammatory response
PBMCs are a population of immune cells consisting of 70-90% lymphocytes (T cells, B cells, and NK cells), 10-30% monocytes, and 1-2% DCs. In order to determine the effects of RSV infection on PBMCs in terms of HMGB1 release, we infected PBMCs with RSV at an MOI of 3 and measured HMGB1 levels in the cell-free supernatants and total cell lysates. RSV did not induce the release of HMGB1 from PBMCs, indicating that RSV-induced HMGB1 release was cell specific (Fig. 4A) . To understand the mechanisms associated with immune cell activation by HMGB1, we next examined the levels of NF-kB and P38 MAPK phosphorylation in PBMCs in response to purified HMGB1 treatment and RSV infection. PBMCs were incubated with rHMGB1 and sHMGB1 at 100 ng/ml in the presence or absence of RSV, and we measured NF-kB and P38 MAPK activation by WB. Addition of purified HMGB1 alone significantly activated the NF-kB and P38 MAPK signaling pathways, but activation was diminished in the presence of RSV (Fig. 4A ). Densitometric analysis of the WB showed that rHMGB1 and sHMGB1 treatment of PBMCs increased pP65 levels by ∼1.6-fold and 4.1-fold, respectively. RSV alone caused about a 2.7-fold increase in pP65 levels, whereas in the presence of rHMGB1, phosphorylation was decreased by 0.6-fold, and in the presence of sHMGB1 it was decreased by 0.2-fold. pP38 MAPK levels were increased by 4.6-fold with rHMGB1 treatment, and a 10.6-fold increase was observed in response to sHMGB1 treatment versus untreated cells. RSV infection alone induced a 1.1-fold increase compared with uninfected cells, whereas RSV in combination with sHMGB1 increased P38 MAPK phosphorylation by 2.8-fold (Fig. 4B) . These results showed that HMGB1 activates both the P38 MAPK and NF-kB signaling pathways to promote the inflammatory responses in PBMCs. Our studies showed that RSV-induced HMGB1 secretion from AECs did not induce proinflammatory mediator release by A549 (29) and SAE cells (Supplemental Fig. 1A,  1B ), but instead activated human monocytes to promote an inflammatory response (29) . In this study, we tested the effects of purified HMGB1 on proinflammatory mediator release in PBMCs. Primary human PBMCs were pretreated with purified HMGB1 (100 ng/ml) in the presence or absence of RSV, and cell-free supernatants were used to measure cytokine/chemokine release by a Bio-Plex assay (Fig. 5 ).
Our results show that RSV infection alone induced a significant (Fig. 5B ). Both RSV and HMGB1 synergistically increased IL-1RA, IL-10, G-CSF, and TNF-a secretion (Fig. 5C ). We also observed an antagonistic effect of HMGB1 on IP-10 and MCP-1. These results indicate that HMGB1 released from AECs can provide danger signals to neighboring immune cells in the airways and promote inflammation and also provide a synergistic signal in eliciting proinflammatory gene expression in RSV-infected human PBMCs.
HMGB1 activated NF-kB and MAPK signaling pathways in primary human monocytes to promote an inflammatory response
Monocytes are leukocytes made in the bone marrow that then travel through blood to tissues, where they can differentiate into MFs and DCs, which play an important role in the defense against invading microbes and in inflammation. Our previous studies showed that RSV did not induce HMGB1 release from human monocytes but activated these cells to induce release of proinflammatory mediators (29) . In the current study, we examined the effects of HMGB1 on NF-kB and P38 MAPK signaling pathway activation in human monocytes to understand HMGB1's proinflammatory role in inducing an inflammatory response to RSV infection. Addition of purified HMGB1 to monocytes significantly activated both signaling pathways (Fig. 6A, 6B ). Densitometric analysis of the WB showed that rHMGB1 treatment of human primary monocytes increased pP65 levels by 2.11-fold, whereas RSV infection alone induced a 2.87-fold increase when compared with uninfected cells (Fig. 6B ). pP38 MAPK levels were increased by 3.8-fold with rHMGB1 treatment, whereas RSV infection alone induced 4.64-fold compared with uninfected cells (Fig. 6B ). There was a significant decrease in both pP65 (22%) and pP38 (21%) levels in RSV-infected and rHMGB1-treated cells (Fig. 6A, 6B ). To confirm these results, we also examined the effect of purified HMGB1 on THP-1 monocytes and observed similar findings (Supplemental Fig. 2A, 2B ), suggesting the activation of P38 MAPK and NF-kB signaling pathway by HMGB1 in monocytes. Addition of rHMGB1 (100 ng/ml) to human primary monocytes in the presence or absence of RSV induced a significant release of cytokines/chemokines [( Fig. 7  (29) ]. Our results show that RSV infection alone induced a significant level of secretion of IL1-RA, IL-10, FGF-basic, and VEGF (Fig. 7A ), whereas RSV infection as well as rHMGB1 treatment of cultured human monocytes significantly induced the release of proinflammatory mediators, including IL-1b, IL-6, IL-8, TNF-a, IP-10, GMCSF, MCP-1, MIP-1a, MIP-1b, IFN-g, and RANTES (Fig. 7B ). Both RSV and HMGB1 synergistically increased IL-12 and G-CSF secretion (Fig.  7C ). We observed similar results with THP-1 monocytes (Supplemental Fig. 3 ).
Effect of RSV infection on HMGB1 release in human MFs
Monocytes/MFs play a central role in orchestrating the immune and inflammatory responses to infection and injury. Our previous studies have shown that RSV infection causes the translocation of HMGB1 from the nucleus to the cytoplasm and subsequently to the extracellular space in AECs (29) . Because WB results did not detect the release of HMGB1 in monocyte-derived human MFs in response to RSV infection (Fig. 8A, 8B ), we performed immunofluorescence microscopic studies to determine the localization of HMGB1. MFs were immunostained with HMGB1 Abs after 24 h p.i. in the presence or absence of RSV. As a positive control, cells were treated with LPS (100 ng/ml). HMGB1 was predominantly present in the nucleus, as indicated by nuclear localization in uninfected cells; however, in RSV-infected cells, HMGB1 accumulated at the periphery within the cytoplasm. In LPS-treated cells, HMGB1 levels were significantly reduced as a result of its increased extracellular release (Fig. 8C) . These results were further confirmed by WB analysis of uninfected, RSV-infected, and LPS-treated MFs, where we observed decreased nuclear HMGB1 levels with a concomitant increase in the cytoplasmic levels of RSV-infected cells, whereas with LPS treatment both nuclear and cytoplasmic HMGB1 levels were significantly decreased confirming its extracellular release (Fig. 8D ).
Effects of HMGB1 on NF-kB and P38 MAPK signaling pathway activation and proinflammatory cytokine/chemokine release in human primary MFs
Alveolar MFs play a central role in the host defense against respiratory pathogens by initiating innate and adaptive immune responses, which are also a primary source of proinflammatory cytokines and chemokines. In this study, we investigated the effects of HMGB1 on NF-kB and P38 MAPK signaling pathway activation and on proinflammatory mediator release in primary human MFs to further explore the regulatory mechanisms associated with MFs activation by HMGB1. Our results showed that HMGB1 activated the NF-ΚB signaling pathway in MFs when added at a concentration of 100 ng/ml, which is equivalent to the amount secreted by AECs after RSV infection (29) (Fig. 8A, 8B, Supplemental Fig. 2C, 2D ). P38 MAPK activation was observed only in the presence of RSV. Densitometric analysis of the WB showed that rHMGB1 and sHMGB1 treatment of monocyte-derived MFs increased pP65 levels by 1.8-fold and 0. 8-fold, respectively, and RSV infection alone induced 1.14-fold compared with uninfected cells. Addition of HMGB1 to RSVinfected cells did not change the phosphorylation of P65 when compared with RSV infection alone. Addition of HMGB1 to human MFs decreased the pP38 MAPK level significantly compared with uninfected cells, but in the presence of RSV, sHMGB1 increased the pP38 levels by 34% compared with RSV alone (Fig. 8A, 8B) . Similar findings were observed with THP-1 monocyte-derived MFs (Supplemental Fig. 2C, 2D) . These results demonstrated that HMGB1 activated both P38 MAPK and NF-kB signaling pathways in human MFs.
Our results also showed that addition of rHMGB1 (100 ng/ml) to human MFs in the presence or absence of RSV induced significant release of cytokines/chemokines ( Fig. 9 ). RSV infection alone induced significant secretion of MCP-1 (Fig. 9A) , whereas RSV infection as well as rHMGB1 treatment to cultured human MFs significantly induced the release of proinflammatory mediators, including IL1-RA, IL-6, IL-8, TNF-a, IP-10, GM-CSF, MIP-1a, MIP-1b, and RANTES (Fig. 9B ). Both RSV and HMGB1 synergistically increased IL-12, G-CSF, and IFN-g secretion (Fig. 9C ). We observed similar results with THP-1 monocytederived MFs (Supplemental Fig. 4 ).
HMGB1 activates NF-kB and P38 MAPK signaling pathways and triggers the release of proinflammatory cytokines/chemokines in human primary EOS
EOS are the leukocytes produced in the bone marrow that migrate to tissues throughout the body to fight against infections. In this study, we examined the effects of HMGB1 on NF-kB and P38 MAPK signaling pathway activation and proinflammatory mediator release in primary human EOS. RSV infection did not induce the release of HMGB1 in EOS, similar to that observed in other immune cells; however, HMGB1 (100 ng/ml) activated NF-ΚB and P38 MAPK in EOS (Fig. 10A, 10B ). Addition of rHMGB1 to EOS increased the phosphorylation of P65 and P38 MAPK significantly, by 7-and 3.3-fold, respectively, compared with uninfected cells. In the presence of RSV infection, rHMGB1 increased pP65 levels by 42% compared with RSV alone, which was 2.1-fold compared with uninfected cells (Fig. 10A, 10B) . Similar findings were observed with EOL1 cells (Supplemental Fig. 2E,  2F) . These results confirmed that HMGB1 induced activation of both P38 MAPK and NF-kB signaling pathways in human EOS.
Addition of purified HMGB1 to human primary EOS in the presence of RSV significantly induced the release of IL-8 and PDGF (Fig. 10C ). Addition of HMGB1 to EOL1 cells significantly induced cytokine and chemokine release (Supplemental Fig. 2G ).
HMGB1 activates NF-kB and P38 MAPK and triggers proinflammatory mediator release in human primary monocyte-derived DCs
DCs are the APCs that function to process Ags and present them to T cells to promote immunity to foreign Ags. They also secrete cytokines to regulate immune responses. In this study, we tested the effect of HMGB1 on NF-kB and P38 MAPK signaling pathway activation as well as proinflammatory mediator release in primary human DCs. RSV infection did not induce the release of HMGB1 in DCs, whereas purified HMGB1 activated NF-ΚB and P38 MAPK signaling pathway (Fig. 11A, 11B ). Addition of rHMGB1 to human primary DCs increased the phosphorylation of P65 and P38 MAPK significantly, by 0.94-and 1.5-fold, respectively, compared with uninfected cells. Yet in the presence of RSV, FIGURE 6 . The effect of purified HMGB1 on NF-kB and P38 MAPK activation in human primary monocytes. Monocytes were treated with rHMGB1 or LPS (100 ng/ml) and mock-infected or infected with RSV at an MOI of 3. Cell-free supernatants and total cell lysates were prepared after 24 h p.i. to measure HMGB1, pP65, and pP38 by WB (A). Densitometric analyses of WB band intensities were performed using ImageJ software and were normalized to internal loading control b-actin for lysates (B). The figure is representative of three independent experiments, and quantified results are shown in bar graphs. *p , 0.05, **p , 0.005. rHMGB1 increased the P65 and P38 MAPK phosphorylation by 33 and 37%, respectively, compared with RSV alone, which was a 1.26-and 5.2-fold increase, respectively, compared with uninfected cells (Fig. 11A, 11B ). RSV infection alone significantly induced the release of IL1-1b, IL-1ra, IL-4, IL-6, IL-10, IL-12, IL-17, Eotaxin, FGF basic, G-CSF, MCP-1, and MIP-1b from human DCs (Fig. 12A ). Addition of purified HMGB1 to human DCs as well as RSV infection induced significant release of IL-8, GM-CSF, IP-10, IFN-g, MIP-1a, RANTES, and TNF-a (Fig. 12B) . Both RSV and HMGB1 synergistically increased PDGF and VEGF (Fig. 12C ).
Discussion
HMGB1 is a novel inflammatory signaling molecule that contributes to the pathogenesis of many inflammatory diseases (24, (46) (47) (48) . In this study, we demonstrated that purified HMGB1 induced a proinflammatory response in human immune cells in vitro that was characterized by activation of NF-kB and P38 MAPK signaling pathways, increased production of proinflammatory cytokines and chemokines, and the involvement of multiple intracellular mechanisms in RSV-induced HMGB1 secretion. Altogether, this evidence points to HMGB1 as an important proinflammatory mediator that contributes to RSV pathogenesis.
The first cells encountered by RSV are typically AECs; subsequent cellular contact is with innate immune cells such as monocytes, alveolar MFs, and DCs in the airways, which produce significant levels of proinflammatory cytokines, a response to viral infection that helps to control adaptive immunity by interaction with Th cells (49) . RSV primarily affects AECs, but immune cells play a role in the immunopathology of RSV infection and are important components for the antiviral response. RSV infection induces a range of proinflammatory cytokine/chemokine and growth factor released by A549 and SAE cells (33, 40, 50) and have also been detected in nasopharyngeal secretions in RSV-infected infants (29) . Although RSV-induced proinflammatory cytokines have been studied in AECs, there are no extensive studies in immune cells or on the proinflammatory role of extracellular HMGB1 in various immune cell activation. In this study, we evaluated the proinflammatory effects of HMGB1 on RSV infection in AECs (A549 and SAE) and multiple types of immune cells (PBMCs, monocytes, MFs, EOS, and DCs). HMGB1's effects on NF-kB and P38 MAPK signaling pathway activation and production of cytokines and chemokines were also examined. In this study, we show that purified human rHMGB1 and sHMGB1 treatment caused phosphorylation of NF-kB and P38 MAPK in AECs and several immune cells (Figs. 1, 4, 6, 8, 10, 11) . The present study also demonstrated that RSV-induced HMGB1 extracellular release by AECs is mediated by NF-kB, as inhibition of NF-kB signaling significantly blocked HMGB1 release ( Fig. 2A ) whereas activation of NF-kB enhanced the extracellular release of HMGB1 in RSV-infected A549 cells ( Fig. 2B ), suggesting the involvement of NF-kB signaling in RSV-induced HMGB1 release from AECs. Previous studies have also shown the involvement of NF-kB signaling in HMGB1 release (51, 52) . HMGB1 functions via interactions with TLRs and RAGE (19, 53). TLR4, a crucial innate immune pattern recognition receptor, plays an important role in regulating the immune response and inflammatory reaction (54) . Moreover, HMGB1 is an important ligand of TLR4 that induces the release of proinflammatory cytokines (55, 56) . HMGB1-TLR4 signaling induces the activation of MAPK and NF-kB (57) , and the activation of NF-kB leads to the increased release of various proinflammatory cytokines, including IL-1b, IL-6, and TNF-a (58) (59) (60) . The release of proinflammatory cytokines can lead to the recruitment of inflammatory cells into the pulmonary microvasculature (61, 62) . In this study, using neutralizing Abs, we demonstrated that HMGB1 secretion from AECs was TLR4 dependent (Fig. 3A) and that blocking TLR4 signaling decreased the RSV-induced NF-kB phosphorylation (Fig. 3A ) compared with RAGE ( Fig. 3B ), suggesting a role for TLR4 in RSV-induced HMGB1 secretion, which is mediated through the NF-kB pathway. Our results showed that the molecular mechanism of HMGB1 release from AECs in response to RSV infection was mediated by both the NF-kB and TLR4 pathways, suggesting an important role of TLR4/NF-kB pathway in RSV-induced HMGB1 release. The underlying mechanism involves, at least in part, inhibition of TLR4/NF-kB-dependent signaling pathway, which provides new evidence for therapeutic application of HMGB1 release blockade to target inflammatory processes in respiratory viral infections.
In this study, we used various immune cells, including human primary cells and cell lines as well as AECs, to investigate the proinflammatory effects of HMGB1. We compared cytokine release from AECs (A549 and SAE), PBMCs, PBMC-derived monocytes, MFs, DCs, and EOS as well as THP-1 monocytes, THP-1 monocyte-derived MFs, and EOL1 cells after treatment with purified human rHMGB1 and sHMGB1 in the presence or absence of RSV. We show that purified HMGB1 is a proinflammatory mediator and induces activation of the NF-kB and P38 MAPK signaling pathways and the release of inflammatory cytokines and chemokines. Our previous and current studies show that RSV induces HMGB1 release from AECs and FIGURE 10 . The effect of purified HMGB1 on NF-kB, P38 MAPK activation, and proinflammatory mediator release in primary human EOS. EOS were treated with rHMGB1 (100 ng/ml) and mock-infected or infected with RSV at an MOI of 3. Cell-free supernatants and total cell lysates were prepared after 24 h p.i. to measure HMGB1, pP65, and pP38 by WB (A). Densitometric analysis of WB band intensities were performed using ImageJ software and were normalized to internal loading control b-actin for lysates (B). The figure is representative of three independent experiments, and quantified results are shown in bar graphs. *p , 0.05, **p , 0.005. The concentrations of different proinflammatory mediators in cell-free supernatants were measured by Bio-Plex (C) (n = 2 independent experiments run in triplicate). Proinflammatory mediators stimulated in combination by HMGB1 and RSV infection. *p , 0.05, **p , 0.005 compared with uninfected, RSV-infected, and HMGB1-treated cells. FIGURE 11. The effect of purified HMGB1 on NF-kB and P38 MAPK activation in primary human DCs. Human DCs were treated with rHMGB1 (100 ng/ml) and mock-infected or infected with RSV at an MOI of 3. Cellfree supernatants and total cell lysates were prepared after 24 h p.i. to measure HMGB1, pP65, and pP38 by WB (A). Densitometric analysis of WB band intensities were performed using ImageJ software and were normalized to internal loading control b-actin for lysates (B). The figure is representative of three independent experiments, and quantified results are shown in bar graphs. *p , 0.05, **p , 0.005. that treatment with purified HMGB1 did not have any effect on these cells ( Figs. 1-3, Supplemental Fig. 1A, 1B) (29) . The present study demonstrates that RSV infection does not induce the release of HMGB1 from any of the immune cells but that addition of LPS promotes HMGB1 translocation from the nucleus to the extracellular space (Figs. 4, 6, 8, 10, 11) . Although the addition of HMGB1 to AECs did not itself induce the release of cytokines/chemokines compared with various immune cells (Supplemental Fig. 1A, 1B) (29) , it did activate NF-kB and MAPK signaling pathways (Fig. 1) . Addition of purified HMGB1 to various immune cells induced the release of proinflammatory cytokines and activated NF-kB and MAPK signaling pathways (Figs. 4, 6, 8, 10, 11 ). HMGB1 in the presence of RSV, either additively or synergistically, induced IL-1RA, IL-8, IL-10, TNF-a, G-CSF, MCP-1, MIP-1a, MIP-1b, RANTES, and PDGF release by PBMCs, whereas HMGB1 induced IL-6, IL-8, IL-12, GMCSF, G-CSF, IFN-g, TNF-a, IP-10, MIP-1a, MIP-1b, and RANTES release in both monocytes and MFs (Figs. 5, 7, 9) . Addition of purified HMGB1 to human EOS in the presence of RSV synergistically induced the release of IL-8 and PDGF, whereas in DCs, HMGB1 induced the release of IL-8, GM-CSF, IP-10, IFN-g, MIP-1a, RANTES, TNF-a, PDGF, and VEGF secretion (Figs. 10C, 12 ). HMGB1 induced IL-8, TNF-a, G-CSF, RANTES, IP-10, and MIP-1a release either additively or synergistically by monocytes, MFs, and DCs, suggesting that HMGB1 secreted by AECs in response to RSV infection potentially signals the monocytes/MFs/DCs to release proinflammatory cytokines and chemokines and contributes to RSV pathogenesis. These results also demonstrated that monocytes, MFs, and DCs are the cellular targets for HMGB1's proinflammatory function, suggesting that RSV-induced epithelial HMGB1 can initiate and amplify inflammatory responses in the airways during infection or injury caused by RSV. Previous studies have shown the release of HMGB1 by monocytes/MFs with addition of LPS or proinflammatory cytokines (63) . Others and we have shown that once HMGB1 is released into the extracellular space, it triggers local inflammatory responses by activating neighboring immune cells in the airways to release more proinflammatory cytokines (28, 29, 53, 64) . Previous studies have also shown the activation of signaling pathways and cytokine release by rHMGB1 in human microvascular endothelial cells and mesenchymal stem cells (27, 65) . Upon release, HMGB1 has been shown to stimulate MF function and induce inflammatory response (66, 67) . Our study also demonstrated that RSV-induced HMGB1 secretion activated immune cells to induce not only proinflammatory mediators but also antiinflammatory cytokines, including IL-1RA, IL-4, IL-10, and IFN-g. Previous studies have shown that in addition to the production of proinflammatory mediators such as TNF-a and IL-1b and HMGB1, activated MFs also produce anti-inflammatory cytokines such as IL-10 and TGF-b1, which have suppressive or enhancing effects on the immune and inflammatory responses (68), including pulmonary inflammation (69) . Our study also showed that RSV infection as well as purified HMGB1 significantly induced IP-10 production in AECs as well as in immune cells (Figs. 5, 7, 9, 12, Supplemental Figs. 1A, 1B, 2-4 ). Studies have shown the increased release of IP-10 in RSV/influenza and bacterial coinfection of human monocyte-derived MFs (55) . This is the first study, to our knowledge, to show the proinflammatory effect of purified HMGB1 on activation of several immune cells and multiple signaling pathways, suggesting the involvement of multiple intracellular mechanisms responsible for RSV pathogenesis, with a role for HMGB1 secretion in response to viral challenge. The in vitro cell culture model of RSV infection, along with purified HMGB1 treatment of various human immune cells, demonstrates that RSV induces significant HMGB1 release in AECs, and that sHMGB1 activates immune cells to induce an inflammatory response, suggesting that HMGB1 acts as a signaling molecule to alert the immune system to the potential damage and promote inflammation. Our studies also demonstrate that RSV and HMGB1 synergistically induce significant release of proinflammatory cytokines and chemokines from immune cells, suggesting that human blood leukocytes contribute to the immunopathology of RSV. Additionally, the inflammatory pathways that are activated during RSV infection and HMGB1 treatment provided the significance related to the synergistic induction of proinflammatory mediators. Our observations are consistent with the previous study reported (27) . By focusing on the intracellular mechanisms that regulate inflammatory pathways, we demonstrated a proinflammatory role for HMGB1 in the activation of immune cells.
In summary, our results provide a mechanistic pathway of RSVinduced HMGB1 release in AECs and show that sHMGB1 alerts the host immune system by activating PBMCs, monocytes, and MFs in a TLR4-and RAGE-dependent manner, via NF-kB and P38 MAPK signaling pathway activation, to induce proinflammatory mediator release (Fig. 13 ). Our studies indicate important cross-talk between the HMGB1, NF-kB, TLR, RAGE, and MAPK signaling pathways in the course of RSV infection, with increasing extracellular HMGB1 levels able to induce inflammation, which was mediated through NF-kB and TLR4. The potential involvement of multiple intracellular mechanisms suggests that our findings may be relevant to other respiratory viruses. We hypothesize that RSV-induced NF-kB and TLR4-dependent HMGB1 secretion from AECs activates immune cells to promote the production of proinflammatory mediator and contribute to RSV pathogenesis. Therefore, blocking HMGB1 proinflammatory activities may be an effective therapeutic strategy, not only against RSV-induced lower respiratory tract infections but also against other viruses responsible for human infections.
